This content requires an NEJM.org account. Create a free account now. Already have an account? Sign in .

Quick Take Free Preview

Ublituximab in Relapsing Multiple Sclerosis

Continue to access content

Select an option below:

This content requires an account.

Create Account

Already have an account?

Sign In

Among patients with relapsing MS, the anti–B-cell monoclonal antibody ublituximab lowered relapse rates and reduced brain lesions on MRI, but how it compares with existing treatments is unknown. New research findings are summarized in a short video.

This content requires an NEJM.org account.

Create Account